Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment ID6576
In development
Reference number: GID-TA11773
Expected publication date: TBC
Documents
Documents created during the development process.
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6576